United States Opioid Analgesics Market Analysis-Size Forecast 2032

United States opioid analgesics market is projected to witness a CAGR of 3.64% during the forecast period 2025–2032, growing from USD 12.16 billion in 2024 to USD 16.15 billion in 2032. The growth of the aging population, rising prevalence of chronic diseases, and increasing requirement for products that aid in management of post-operative pain are some of the major factors driving the growth of the opioid analgesics market in the United States. According to the estimates of the Population Reference Bureau, the number of Americans that are 65 and older is expected to witness a 47% increase from 2022 to 2050.

The market’s growth is also supported by the strong presence of major market players, continuous investments in research and developments activities, and increasing healthcare expenditure in the United States. Research institutions and healthcare organizations are focusing on developing safer opioid alternatives and in post-marketing surveillance to monitor adverse events. Additionally, the United States continues to witness increase in the number of surgical procedures, further driving the demand for opioids in acute care setting.

Expansion of the Aging Population Boosts Market Demand

The rapid growth of the aging population is one of the major drivers of the market as the elderly are more prone to age-related chronic conditions such as neuropathic pain and arthritis, among others. In such conditions, the patients often rely on effective pain management solutions, resulting in a higher requirement for opioid analgesics. Additionally, the older population is also more likely to undergo surgical procedures, frequently necessitating postoperative pain relief. They are also susceptible to injuries and degenerative diseases, further amplifying the requirement for potent pain relief solutions. As per the estimates of the Christopher & Dana Reeve Foundation, approximately 18,000 new spinal cord injuries are reported every year in the United States.

Meanwhile, pharmaceutical companies and healthcare professionals are increasingly focusing on personalized medicines and customized pain management strategies in order to align with the unique pain management requirements of the older population.

Click here: https://www.marketsandata.com/industry-reports/united-states-opioid-analgesics-market

United States Opioid Analgesics Market—Forecast to 2032.” I’ve included an executive summary, epidemiology, market definition, drivers & restraints, regulatory & legal context, competitive landscape, segmentation, scenario forecasts (with explicit assumptions and CAGR ranges), methodology, KPIs to monitor, and strategic recommendations. I cite authoritative sources for the most load-bearing facts (prescribing trends, chronic-pain burden, overdose deaths, REMS changes, and national settlement context) so you can trace the evidence and adjust levers in a modeling workbook.

Increasing Focus on Abuse-Deterrent Formulations (ADFs) Supports Market Expansion

The focus on developing ADFs has significantly increased over the past few years in order to address the ongoing opioid crisis by maintaining the pain relief benefits of opioids for genuine patients while reducing the potential for abuse. The Food and Drug Administration (FDA) is actively encouraging the development and introduction of ADFs, promoting collaborations among specialty pharmaceutical companies. For instance, in March 2025, Protega Pharmaceuticals Inc. and Wellgistics Health partnered with each other to enhance pharmacist education and improve patient access to ROXYBOND, the first and only FDA-approved abuse-deterrent immediate-release opioid in the United States. Such initiatives are directed towards addressing the more complicated issue of pain management and opioid prescribing and seek to promote safer opioid utilization and reduce the risks associated with opioid use.

Mergers and Acquisitions Drive Market Growth

Such strategic initiatives are allowing leading pharmaceutical companies to improve their research and development capabilities, expand their product portfolios, and strengthen their market presence. Additionally, pharmaceutical giants are also focusing on mergers and acquisitions due to the major financial challenges faced by various companies during the opioid crisis and opioid-related litigation. For instance, in March 2025, Mallinckrodt Pharmaceuticals plc and Endo Pharmaceuticals Inc. announced a USD 6.7 billion merger that is expected to close in the second half of 2025. Both companies have faced financial challenges due to opioid-related litigation and are seeking to create a more resilient pharmaceutical entity with enhanced resources for innovation and growth, with this merger. This collaboration is also expected to enhance their financial stability and strengthen their position in the market.

The U.S. opioid analgesics market is shifting from high historic prescribing volumes toward a controlled, lower-volume, higher-risk market shaped by intense regulatory oversight, stewardship programs, litigation/settlements and growth of opioid-sparing alternatives. Prescription opioid dispensing rates have fallen materially since 2019, while the public-health focus has moved to illicit fentanyl as the main driver of overdose deaths. These forces reduce unit prescription growth but create parallel markets for abuse-deterrent formulations (ADFs), pain-service support, and OUD (opioid use disorder) treatments. Using transparent levers, our 2032 U.S. revenue scenarios (conservative / base / aggressive) range from $6–18 billion for prescription opioid analgesics depending on pricing, substitution to non-opioid options, litigation outcomes and policy changes. (Key evidence: CDC dispensing rate decline, chronic-pain prevalence, overdose statistics, FDA REMS changes, national settlement programs.)

Retail Pharmacies Hold Major Market Share

Due to their accessibility, extensive reach, and role in dispensing prescription medications, retail pharmacies hold a major share in the United States opioid analgesics market. These pharmacies serve as the primary distribution channel for opioid analgesics for patients suffering from chronic pain, among other medical conditions. Additionally, patients also prefer retail pharmacies due to their convenient nature. Retail pharmacies cater to patients across all regions, including those living in rural and underserved areas. Additionally, retail pharmacies play a vital role in ensuring compliance for opioid use with regulatory guidelines. They are able to monitor prescriptions and dispense the proper dosages while providing counseling to patients regarding the use of opioids. Thus, bolstering the segment’s expansion.

Download Free sample Report

Market definition & scope

• Included: Prescription opioid analgesics sold in the U.S. for acute, postsurgical, cancer-related and chronic non-cancer pain (natural, semi-synthetic and synthetic opioids), plus revenues from branded + generic product sales, abuse-deterrent premium price uplift, and distribution/administration where applicable (Part B infusion settings are rare for opioids; most are outpatient pharmacy).


• Excluded: Illicit opioids (heroin/fentanyl in the street market), opioid use disorder (OUD) treatment market (except where closely tied to analgesic stewardship), OTC analgesics, legal settlements as a revenue stream (we model their market impact, not include settlement funds as market revenue).


• Geography & currency: United States; USD.

Key facts & epidemiology (load-bearing evidence)

• Opioid dispensing rates are falling. The national opioid dispensing rate declined from 46.8 prescriptions per 100 persons in 2019 to 37.5 per 100 persons in 2023 (wide state variation persists). CDC


• Chronic pain burden is large. In 2023, ~24.3% of U.S. adults reported chronic pain in the prior 3 months and ~8.5% had high-impact chronic pain (limits life/work). These cohorts are the primary clinical pool driving long-term analgesic demand. CDC


• Overdose deaths remain elevated but shifted to illicit fentanyl. In 2023 nearly 80,000 opioid-involved overdose deaths occurred (≈76% of ~105,000 drug overdose deaths), with synthetic opioids (fentanyl) dominating the toll. This epidemiology shapes policy and public opinion driving prescribing constraints. CDC


• Regulatory action continues: FDA modified the Opioid Analgesic REMS (OA-REMS) and required participating companies to provide prepaid drug mail-back envelopes for outpatient dispensers (disposal interventions), signaling ongoing active oversight. U.S. Food and Drug Administration


• Legal & funding landscape is large & active: National/state opioid settlements with manufacturers/distributors remain a major contextual driver (multi-billion dollar programs and structural changes in distribution). These settlements shape distributor behavior and contracting.

Scenario assumptions (key levers)

• Base year: 2024 (use market estimate range anchors from industry reports; adjust if you have a proprietary baseline).


• Prescription volume trend: continuing decline in dispensing rates (CDC: 46.8 → 37.5 per 100 persons from 2019→2023). We assume further declines but slower over 2025–2032 as stewardship plateaus. CDC


• Price dynamics: generic penetration keeps ASPs controlled for many molecules, but ADFs & niche branded products may hold price premiums.


• Legal/regulatory shocks: settlement timing (Purdue/Sackler, distributor terms) creates discrete shocks that can either suppress supply or accelerate alternative pathways.

Forecast methodology (recommended, transparent)

1. Epidemiology base: Use NHIS chronic pain prevalence (2023) segmented by age to estimate patient pools who may receive opioids. CDC


2. Prescribing rates: Anchor to CDC dispensing per 100 persons and model decline curves reflecting PDMP and guideline effects. CDC


3. Volume → revenue build: prescriptions × average MME per Rx × ASP (by molecule/brand/generic/ADF).


4. Channel & payer adjustments: split Part D vs commercial vs Medicaid to reflect coinsurance, rebates and passthroughs.


5. Scenario levers: ADF adoption rate/ASP premium, non-opioid substitution rates, litigation/settlement timing (shock events), and PDMP mandate intensity.


6. Validation: benchmark top-down vs bottom-up to vendor market reports (e.g., Future Market Insights, Grand View) and reconcile differences.

About Us:
Markets and Data provides a comprehensive/ panoramic understanding of markets at global, regional, and country levels. Examine changing consumer preferences, emerging challenges, underlying trends, and growth prospects to accelerate your business strategies.

Contact
Mr. Vivek Gupta
5741 Cleveland street,
Suite 120, VA beach, VA, USA 23462
Tel: +1 (757) 343–3258
Email: [email protected]
Website: https://www.marketsandata.com